Ubrogepant
As of the edition of 20 October 2026, Ubrogepant is a small molecule: marketed, first approved in 2019 (US); acts on CALCRL; US protection ends in 2033.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Small molecule
- Brand name
- Ubrelvy
- First approved
- 23 December 2019 (US)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- AbbVie
- Registered trials
- 16, 0 stopped early
- Disease areas
- Nervous system; Pregnancy and women's health; Urinary and reproductive
US protection
US protection ends in 2033.
The last listed US drug-substance patent ends in 2033. The application that gives this date is held by AbbVie.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product6 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 6 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CALCRL | Calcitonin gene-related peptide type 1 receptor | Q16602 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 1 | 0 |
| Phase 1 | 4 | 3 | 1 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 7 | 4 | 3 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 16 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Originator, Applicant and Lead sponsor of trials | 2012 to now |